Adding surgery and radiation to standard therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding surgery to remove the prostate and radiation to visible cancer spots, along with the usual hormone therapy, can help men with newly diagnosed prostate cancer that has spread. It aims to see if this more intensive approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with prostate cancer that has spread to other parts of the body (but not to organs like the liver or lungs).
- You have 1 to 10 visible cancer spots on scans.
- You are willing to start or have recently started (within 2 months) a specific hormone therapy combination (apalutamide plus ADT).
- You are healthy enough for surgery and radiation, with a good performance status.
- You have not had prior chemotherapy, immunotherapy, or other newer hormone therapies for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving prostate removal surgery in addition to standard hormone therapy can help men with advanced prostate cancer that has spread to many places. It aims to see if this combination helps them live longer with a better quality of life.
This study tests if removing the prostate and giving strong hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. It aims to improve how long patients live without the cancer worsening.
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
This trial tests a combination of surgery and radiation to remove as much cancer as possible in men with prostate cancer that has spread to a few spots outside the prostate. It aims to see if this aggressive approach can improve long-term outcomes.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.